Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL112349 | 0.81 | ELANE (0.48) | KMT2AMEN1TP53PABPC1SMN1; SMN2 | |
| SCHEMBL30814447 | 0.80 | KMT2A (0.50) | KMT2AMEN1TP53PABPC1SMN1; SMN2 | |
| SCHEMBL2715939 | 0.80 | KMT2A (0.50) | KMT2AMEN1TP53PABPC1SMN1; SMN2 | |
| SCHEMBL29908323 | 0.78 | PARP1 (0.56) | KMT2AMEN1TP53PABPC1MAPT | |
| SCHEMBL2184004 | 0.77 | SMN1; SMN2 (0.72) | KMT2AMEN1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL2183866 | 0.74 | HDAC1 (0.42) | KMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL27582571 | 0.74 | TP53 (0.46) | KMT2AMEN1TP53PABPC1MAPT | |
| SCHEMBL30814349 | 0.74 | POLB (0.43) | KMT2AMEN1TP53PABPC1MAPT | |
| SCHEMBL12414507 | 0.73 | MGLL (0.51) | KMT2AALDH1A1MAPT | |
| SCHEMBL12414508 | 0.70 | SMN1; SMN2 (0.48) | KMT2ASMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160139162-A1 | Inhibitors Of Fatty Acid Amide Hydrolase And Monoacylglycerol Lipase For Modulation Of Cannabinoid Receptors | NORTHEASTERN UNIVERSITY | 2016-05-19 | — | — | US | disclosed |
| US-20160139162-A1 | Inhibitors Of Fatty Acid Amide Hydrolase And Monoacylglycerol Lipase For Modulation Of Cannabinoid Receptors | NORTHEASTERN UNIVERSITY | 2016-05-19 | — | — | US | disclosed |
| US-20160139162-A1 | Inhibitors Of Fatty Acid Amide Hydrolase And Monoacylglycerol Lipase For Modulation Of Cannabinoid Receptors | NORTHEASTERN UNIVERSITY | 2016-05-19 | — | — | US | disclosed |
| US-9271962-B2 | Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors | NORTHEASTERN UNIVERSITY (US) | 2016-03-01 | — | — | US | disclosed |
| US-9271962-B2 | Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors | NORTHEASTERN UNIVERSITY (US) | 2016-03-01 | — | — | US | disclosed |
| US-9271962-B2 | Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors | NORTHEASTERN UNIVERSITY (US) | 2016-03-01 | — | — | US | disclosed |
| US-20110166138-A1 | Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase for Modulation of Cannabinoid Receptors | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2011-07-07 | — | — | US | disclosed |
| US-20110166138-A1 | Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase for Modulation of Cannabinoid Receptors | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2011-07-07 | — | — | US | disclosed |
| US-20110166138-A1 | Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase for Modulation of Cannabinoid Receptors | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2011-07-07 | — | — | US | disclosed |
| WO-2009117444-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE AND MONOACYLGLYCEROL LIPASE FOR MODULATION OF CANNABINOID RECEPTORS | NORTHEASTERN UNIVERSITY (US) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166138-A1 | Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase for Modulation of Cannabinoid Receptors | FAAH, FAAH2, MGLL | KMT2A 2131/4885MEN1 4627/4885TP53 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.